Clinical Trial Update: Efficacy of a Prebiotic Galactooligosaccharide to Reduce Metabolic Syndrome Risk Factors in Overweight Adults [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/Phase 2 trial evaluated whether a galactooligosaccharide prebiotic could reduce metabolic syndrome risk factors in overweight adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Drugs mentioned

• Galactooligosaccharide (galactooligosaccharide)

Snippet

Sponsor: Clasado | Conditions: Metabolic Syndrome X | Phase 1, Phase 2 | Status: COMPLETED